Enterprise Value
399.1M
Cash
169.5M
Avg Qtr Burn
-14.88M
Short % of Float
23.30%
Insider Ownership
10.71%
Institutional Own.
94.03%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NGN-401 Details Rare genetic disease, Rett syndrome | Phase 1/2 Data readout | |
NGN-101 Details Rare genetic disease, Batten Disease | Phase 1/2 Data readout |